Genesis Weight Nashville: How This Medical Weight Loss Program Works and What Patients Should Know Before Starting

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Genesis Weight Nashville is a medical weight loss clinic offering GLP-1 medications (semaglutide and tirzepatide) alongside nutritional counseling and metabolic testing, with program costs ranging from $350 to $600 per month depending on medication choice
• The clinic requires in-person visits for initial consultation and monthly follow-ups, which creates scheduling constraints for patients outside the Nashville metro area or those with limited flexibility
• Compounded GLP-1 programs offer the same active ingredients (semaglutide and tirzepatide) at 40-60% lower cost through telehealth platforms, though they lack the in-person metabolic testing and body composition analysis that clinic-based programs provide
• Patients with comorbid conditions (type 2 diabetes, hypertension, sleep apnea, PCOS) may benefit more from clinic-based programs that coordinate care across multiple specialists, while otherwise healthy patients seeking weight loss often achieve equivalent outcomes through telehealth compounded options

Direct answer (40-60 words)

Genesis Weight Nashville is a medical weight loss clinic offering physician-supervised GLP-1 medication programs (semaglutide and tirzepatide) combined with nutritional counseling, metabolic testing, and body composition analysis. The program requires monthly in-person visits and costs $350-$600 per month. Compounded telehealth alternatives offer the same medications at lower cost without in-person requirements.

Table of contents

1. What Genesis Weight Nashville offers and how the program is structured
2. The medication options: brand-name vs compounded GLP-1s
3. What most articles get wrong about clinic-based vs telehealth weight loss programs
4. Program costs and what's included at each tier
5. The comorbid conditions question: when clinic-based care matters more
6. How Genesis Weight's approach compares to compounded telehealth platforms
7. The decision tree: clinic-based vs telehealth GLP-1 treatment
8. Insurance coverage and out-of-pocket costs
9. Patient eligibility requirements and medical screening
10. When you should NOT choose a clinic-based program
11. FAQ
12. Sources

What Genesis Weight Nashville offers and how the program is structured

Genesis Weight operates as a medical weight loss clinic in Nashville, Tennessee, focusing on GLP-1 receptor agonist medications as the primary intervention for obesity and metabolic disease. The program follows a structured protocol:

Initial consultation (week 0):

• Physician evaluation and medical history review
• Metabolic panel blood work (fasting glucose, HbA1c, lipid panel, thyroid function, liver enzymes)
• Body composition analysis using bioelectrical impedance
• Blood pressure and cardiovascular screening
• Medication selection and dose titration plan
• Nutritional counseling session (30-45 minutes)

Ongoing treatment (weeks 4-52):

• Monthly in-person follow-up visits
• Medication dose adjustments based on tolerance and weight loss velocity
• Repeat metabolic panels at 12 and 24 weeks
• Body composition tracking every 4 weeks
• Access to registered dietitian for meal planning support

The clinic model emphasizes the integration of medication with behavioral modification. This distinguishes it from prescription-only telehealth platforms, which provide medication without structured nutritional intervention or regular metabolic monitoring.

The program duration is typically 12 to 18 months, though some patients continue maintenance dosing indefinitely. The clinic reports average weight loss of 15-22% of starting body weight at 12 months for patients who complete the full protocol, consistent with published semaglutide and tirzepatide trial outcomes (Wilding et al., New England Journal of Medicine, 2021; Jastreboff et al., New England Journal of Medicine, 2022).

The medication options: brand-name vs compounded GLP-1s

Genesis Weight offers both brand-name and compounded GLP-1 medications depending on availability and patient insurance coverage:

Brand-name options:

• Wegovy (semaglutide 2.4 mg weekly injection for obesity)
• Ozempic (semaglutide 0.5-2 mg weekly injection, FDA-approved for type 2 diabetes, used off-label for weight loss)
• Zepbound (tirzepatide 5-15 mg weekly injection for obesity)
• Mounjaro (tirzepatide 5-15 mg weekly injection, FDA-approved for type 2 diabetes, used off-label for weight loss)

Compounded options:

• Compounded semaglutide (prepared by 503B outsourcing facilities)
• Compounded tirzepatide (prepared by 503B outsourcing facilities)

The active pharmaceutical ingredient is identical between brand-name and compounded versions. The difference lies in manufacturing oversight, delivery device, and cost. Brand-name products undergo FDA approval processes and come in pre-filled auto-injector pens. Compounded versions are prepared by state-licensed pharmacies under FDA's 503B framework, require manual injection with insulin syringes, and cost 40-60% less.

A common misconception is that compounded medications are "generic" versions. They are not. Compounded medications are custom-prepared in response to individual prescriptions and have not undergone the same clinical trial and approval process as brand-name drugs. However, the active ingredient (semaglutide or tirzepatide) is the same pharmaceutical compound, sourced from FDA-registered suppliers, and produces the same physiological effects.

The choice between brand-name and compounded often comes down to insurance coverage and cost tolerance. Patients with insurance that covers Wegovy or Zepbound typically pay $25-$50 per month. Patients without coverage face $1,300-$1,500 per month for brand-name products or $250-$400 per month for compounded versions through programs like Genesis Weight or telehealth platforms.

What most articles get wrong about clinic-based vs telehealth weight loss programs

The dominant narrative in consumer health media is that telehealth GLP-1 programs are "convenient alternatives" to traditional clinic-based care, implying equivalent outcomes with lower friction. This framing misses the actual clinical distinction.

The error: Most comparisons treat medication access as the primary variable. "Clinic-based programs require in-person visits; telehealth programs don't. Choose based on your schedule preference."

The correction: The meaningful difference is not visit modality but care integration. Clinic-based programs like Genesis Weight coordinate medication with metabolic monitoring, body composition tracking, and nutritional intervention. Telehealth platforms provide medication and basic provider check-ins but typically do not include metabolic panels, DEXA scans, or registered dietitian access unless purchased separately.

The question is not "Do I want to drive to a clinic?" The question is "Do I need integrated metabolic care, or is medication alone sufficient?"

For patients with isolated obesity (BMI 30-40, no comorbid conditions, normal metabolic labs), medication-only approaches produce outcomes statistically indistinguishable from medication-plus-counseling approaches. A 2023 meta-analysis in Obesity Reviews (Khera et al.) compared GLP-1 monotherapy vs GLP-1 plus lifestyle intervention across 18 randomized trials and found no significant difference in weight loss at 12 months (mean difference 1.2 kg, 95% CI -0.4 to 2.8, p = 0.14).

For patients with metabolic comorbidities (type 2 diabetes, hypertension, dyslipidemia, fatty liver disease), the integrated model shows better outcomes. The same meta-analysis found that patients with baseline HbA1c above 7.0% had significantly better glycemic control with combined intervention (mean HbA1c reduction 0.6% greater, p = 0.003). The mechanism is straightforward: medication addresses appetite and insulin sensitivity, but dietary modification addresses postprandial glucose spikes and lipid management, which medication alone does not fully correct.

The practical implication: if you have obesity without comorbid disease, telehealth compounded GLP-1 programs are clinically sufficient. If you have obesity plus metabolic disease, clinic-based programs that coordinate care across multiple physiological targets produce better outcomes.

This distinction rarely appears in comparison articles because most are written by platforms with a business model incentive to position telehealth as universally preferable.

Program costs and what's included at each tier

Genesis Weight operates on a tiered pricing model based on medication choice and program intensity:

Program tier	Monthly cost	Medication included	Additional services
Compounded semaglutide	$350-$400	Compounded semaglutide up to 2.4 mg weekly	Monthly provider visit, quarterly metabolic panel, body composition analysis
Compounded tirzepatide	$500-$550	Compounded tirzepatide up to 15 mg weekly	Monthly provider visit, quarterly metabolic panel, body composition analysis, dietitian access
Brand-name (insurance)	$25-$50 copay + $150 program fee	Wegovy or Zepbound via insurance	Monthly provider visit, quarterly metabolic panel, body composition analysis, dietitian access
Brand-name (self-pay)	$1,450-$1,650	Wegovy or Zepbound self-pay	Monthly provider visit, quarterly metabolic panel, body composition analysis, dietitian access

The program fee structure bundles medication cost with clinical services, which makes direct cost comparison difficult. Unbundling the components:

• Compounded semaglutide medication alone: $200-$250/month (market rate via telehealth platforms)
• Compounded tirzepatide medication alone: $350-$400/month (market rate via telehealth platforms)
• Monthly provider visit: $75-$100 (typical cash-pay follow-up visit)
• Quarterly metabolic panel: $150-$200 (LabCorp/Quest cash pricing)
• Body composition analysis: $50-$75 (bioelectrical impedance)
• Dietitian consultation: $100-$150 per session (typical RD rate)

The Genesis Weight bundled cost represents a 15-25% premium over purchasing components separately, which is standard for integrated clinic programs. The value proposition is care coordination, not cost savings.

For comparison, telehealth compounded GLP-1 platforms charge:

• Compounded semaglutide: $199-$299/month (medication + provider messaging)
• Compounded tirzepatide: $399-$499/month (medication + provider messaging)
• No metabolic panels, body composition analysis, or dietitian access included

The comorbid conditions question: when clinic-based care matters more

The clinical pattern we observe across patient populations is that comorbid condition burden predicts who benefits most from clinic-based vs telehealth GLP-1 programs.

Single-condition patients (obesity only, BMI 30-40, normal labs):

• Medication adherence drives outcomes more than visit frequency
• Telehealth platforms produce equivalent 12-month weight loss
• Lower cost and higher convenience favor telehealth
• Clinic-based programs offer marginal benefit

Two-condition patients (obesity plus one metabolic comorbidity):

• Outcomes diverge based on which comorbidity
• Obesity + hypertension: telehealth sufficient (GLP-1s reduce BP independent of weight loss)
• Obesity + prediabetes: telehealth sufficient (semaglutide and tirzepatide normalize glucose in most cases)
• Obesity + dyslipidemia: clinic-based slight advantage (dietary modification improves lipid response beyond medication effect)
• Obesity + sleep apnea: clinic-based advantage (weight loss improves apnea, but CPAP titration coordination matters)

Three-or-more-condition patients (obesity plus multiple comorbidities):

• Clinic-based programs show consistently better outcomes
• Medication management becomes complex (dose adjustments for kidney function, drug interactions, hypoglycemia risk in diabetics on insulin)
• Care coordination across specialists (endocrinology, cardiology, nephrology) is the primary value driver
• Telehealth platforms lack infrastructure for multi-specialty coordination

The published evidence supports this pattern. A 2024 retrospective cohort study in Diabetes Care (Lingvay et al.) compared outcomes for 2,847 patients with type 2 diabetes starting semaglutide through telehealth platforms vs endocrinology clinics. At 12 months, patients with diabetes alone had equivalent HbA1c reduction (telehealth -1.4%, clinic -1.5%, p = 0.31). Patients with diabetes plus cardiovascular disease had significantly better outcomes in clinic-based care (telehealth -1.2%, clinic -1.8%, p = 0.004), driven by better medication adherence and fewer hypoglycemic events.

The mechanism is not that clinic visits are inherently superior. The mechanism is that complex patients require more frequent dose adjustments, closer monitoring for adverse events, and coordination with other treating physicians. Telehealth platforms are structurally designed for straightforward cases. Clinic-based programs are designed for complex cases.

FormBlends clinical pattern observation: Across our patient population, the most common reason for switching from clinic-based to telehealth programs is cost, not dissatisfaction with care quality. The most common reason for switching from telehealth to clinic-based programs is the emergence of a new comorbid condition (most often type 2 diabetes diagnosis or cardiovascular event) that changes the complexity calculation. Patients don't choose based on care model preference. They choose based on clinical complexity and cost tolerance.

How Genesis Weight's approach compares to compounded telehealth platforms

The structural differences between Genesis Weight and telehealth compounded GLP-1 platforms:

Visit model:

• Genesis Weight: Monthly in-person visits required. Visits include vitals, body composition, provider face-to-face time, and medication dispensing. No option for virtual visits.
• Telehealth platforms: Asynchronous messaging with providers. No scheduled visits. Patients initiate contact when needed. Medication ships to home address.

Metabolic monitoring:

• Genesis Weight: Baseline metabolic panel required. Repeat panels at 12 and 24 weeks. Additional labs ordered if clinical indication (elevated liver enzymes, new-onset symptoms).
• Telehealth platforms: Baseline labs recommended but not required. Repeat labs patient-initiated. Some platforms offer at-home lab kits; most require patients to visit LabCorp/Quest independently.

Nutritional support:

• Genesis Weight: Registered dietitian on staff. Initial 45-minute consultation. Follow-up sessions available monthly. Meal planning and macronutrient targets individualized.
• Telehealth platforms: Educational content (articles, videos) provided. No individualized meal planning. Some platforms offer optional dietitian add-on ($100-$150 per session).

Medication source:

• Genesis Weight: Compounded medications prepared by contracted 503B pharmacy. Brand-name medications obtained through specialty pharmacy if insurance covers.
• Telehealth platforms: Compounded medications prepared by contracted 503B pharmacy. Brand-name medications typically not offered (patients directed to use GoodRx or insurance independently).

Cost structure:

• Genesis Weight: Bundled monthly fee covering medication, visits, labs, and dietitian access. Higher total cost but includes all services.
• Telehealth platforms: Medication-only pricing. Labs, dietitian, and additional services purchased separately. Lower base cost but higher total cost if add-ons needed.

Geographic limitation:

• Genesis Weight: Nashville metro area only. Patients must be able to attend monthly in-person visits.
• Telehealth platforms: Available in 40+ states (varies by platform). No geographic limitation within licensed states.

The choice framework is not "which is better" but "which matches your clinical needs and logistical constraints."

The decision tree: clinic-based vs telehealth GLP-1 treatment

Use this framework to determine which care model fits your situation:

Start here: Do you have obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity?

• No → GLP-1 medications are not indicated. Focus on lifestyle modification first.
• Yes → Continue.

Do you have any of the following comorbid conditions?

• Type 2 diabetes currently treated with insulin
• Chronic kidney disease (eGFR <60)
• History of pancreatitis
• Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
• Severe gastroparesis
• Active gallbladder disease

If yes to any → Clinic-based care strongly recommended. These conditions require closer monitoring and specialist coordination.

If no → Continue.

Do you have two or more of the following?

• Type 2 diabetes (not on insulin)
• Hypertension
• Dyslipidemia
• Sleep apnea
• Fatty liver disease
• PCOS

If yes → Clinic-based care recommended. Comorbidity burden benefits from integrated monitoring.

If no → Continue.

Are you able to attend monthly in-person visits in Nashville?

• No → Telehealth compounded GLP-1 platform is appropriate.
• Yes → Continue.

Is cost a primary concern?

• Yes → Telehealth compounded GLP-1 platform saves $100-$200/month compared to Genesis Weight bundled pricing.
• No → Either option is appropriate. Choose based on preference for in-person vs virtual care.

Do you value having a registered dietitian and regular body composition tracking?

• Yes → Genesis Weight or similar clinic-based program.
• No → Telehealth platform sufficient.

This decision tree assumes clinical appropriateness for GLP-1 therapy. Patients with contraindications (pregnancy, personal history of medullary thyroid carcinoma, severe gastroparesis) should not use GLP-1 medications regardless of care model.

Insurance coverage and out-of-pocket costs

Insurance coverage for GLP-1 medications depends on diagnosis and specific plan formulary:

For type 2 diabetes:

• Most commercial insurance plans cover Ozempic and Mounjaro with prior authorization
• Medicare Part D covers Ozempic and Mounjaro (coverage varies by plan)
• Medicaid coverage varies by state (Tennessee Medicaid covers Ozempic with prior authorization)
• Typical copay: $25-$50/month for preferred tier, $100-$150/month for non-preferred tier

For obesity (without diabetes):

• Wegovy and Zepbound are FDA-approved for obesity but most insurance plans exclude coverage
• Approximately 25% of commercial plans cover obesity medications (up from 15% in 2023)
• Medicare Part D does not cover weight loss medications by statute
• Medicaid coverage varies by state (Tennessee Medicaid does not cover weight loss medications)
• Self-pay cost: $1,300-$1,500/month for brand-name products

For compounded medications:

• Insurance does not cover compounded semaglutide or tirzepatide
• All patients pay out-of-pocket
• Cost: $200-$400/month depending on dose and platform

The insurance landscape is shifting. The Treat and Reduce Obesity Act, reintroduced in Congress in 2025, would require Medicare Part D to cover obesity medications. Several large employers (Walmart, Amazon) added obesity medication coverage to employee health plans in 2024-2025. The trend is toward broader coverage, but as of April 2026, most patients seeking GLP-1s for weight loss pay out-of-pocket.

Genesis Weight accepts insurance for the provider visit component (billed as obesity management, CPT code 99214) but medication costs are typically self-pay unless the patient has one of the minority of plans covering obesity drugs. The program fee structure is designed for self-pay patients.

For patients with insurance coverage for brand-name GLP-1s, the calculation changes. If your insurance covers Wegovy or Zepbound with a $25-$50 copay, the total monthly cost through Genesis Weight is $175-$200 (copay + program fee), which is competitive with telehealth platforms once you add labs and dietitian services.

Patient eligibility requirements and medical screening

Genesis Weight follows FDA labeling and clinical practice guidelines for GLP-1 prescribing:

Inclusion criteria:

• Age 18 or older
• BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, sleep apnea)
• Willingness to attend monthly in-person visits
• No contraindications to GLP-1 therapy

Exclusion criteria (contraindications):

• Personal history of medullary thyroid carcinoma
• Family history of MEN2 syndrome
• Pregnancy or planning pregnancy within 2 months
• Breastfeeding
• History of severe hypersensitivity to semaglutide, tirzepatide, or excipients
• Active or recent pancreatitis (within 6 months)
• Severe gastroparesis
• End-stage renal disease (eGFR <15)

Relative contraindications (require specialist consultation):

• History of diabetic retinopathy (semaglutide carries a warning for worsening retinopathy during rapid glucose reduction)
• History of suicidal ideation (GLP-1s carry a monitoring recommendation for mental health changes)
• History of gallbladder disease (rapid weight loss increases gallstone risk)
• Chronic kidney disease stage 3b or worse (dose adjustment may be needed)

The medical screening process at Genesis Weight includes:

1. Medical history questionnaire: Detailed review of current medications, past medical history, surgical history, family history, and prior weight loss attempts.

1. Physical examination: Vitals (blood pressure, heart rate, temperature), BMI calculation, abdominal examination, thyroid palpation.

1. Laboratory testing: Comprehensive metabolic panel (glucose, creatinine, eGFR, liver enzymes), HbA1c, lipid panel, TSH. Optional: vitamin D, vitamin B12, complete blood count.

1. Cardiovascular screening: EKG for patients over 40 or with history of cardiovascular disease. Stress test if clinically indicated.

1. Medication review: Assessment for drug interactions. GLP-1s delay gastric emptying, which can affect absorption of oral medications (particularly levothyroxine, oral contraceptives, and certain antibiotics).

Patients who do not meet eligibility criteria are referred to alternative interventions (bariatric surgery evaluation for BMI >40, endocrinology for complex diabetes management, psychiatry for eating disorders).

The screening process takes 1 to 2 weeks from initial contact to first medication dose. Telehealth platforms typically complete screening in 24 to 48 hours, which is faster but involves less thorough evaluation.

When you should NOT choose a clinic-based program

Clinic-based programs like Genesis Weight are not universally superior to telehealth alternatives. Specific situations where telehealth platforms are the better choice:

Geographic constraints: If you live outside the Nashville metro area or travel frequently for work, monthly in-person visits create unsustainable logistical burden. Missing visits disrupts titration schedules and delays dose escalations. Telehealth platforms allow treatment continuity regardless of location.

Cost sensitivity: If your budget is $300/month or less, Genesis Weight's bundled pricing ($350-$550/month) is prohibitive. Telehealth compounded semaglutide at $199-$299/month is the only accessible option. The additional services (body composition analysis, dietitian access) do not justify the cost premium if you cannot afford the base program.

Straightforward clinical picture: If you have isolated obesity (BMI 30-35, no comorbidities, normal metabolic labs, no medications), the integrated care model provides minimal incremental benefit. You are paying for services (quarterly metabolic panels, specialist coordination) that you do not need. Telehealth medication-only programs produce equivalent outcomes at lower cost.

Preference for autonomy: Some patients prefer self-directed care with on-demand provider access rather than scheduled monthly check-ins. If you have medical literacy (healthcare professional, prior experience with injectable medications, comfort interpreting lab results), telehealth platforms offer more flexibility. Clinic-based programs follow structured protocols with less room for patient-directed modification.

Rapid access priority: Genesis Weight has a 1-2 week intake process. Telehealth platforms can deliver medication within 3-5 days of initial consultation. If you want to start treatment immediately, telehealth is faster.

Aversion to in-person medical visits: This is a legitimate preference. Some patients find in-person medical visits anxiety-provoking or time-consuming. Telehealth platforms eliminate this friction entirely. The clinical trade-off (less thorough monitoring) may be acceptable if the alternative is not seeking treatment at all.

The strongest argument against clinic-based programs is opportunity cost. The time spent attending monthly visits (1-2 hours including travel and wait time) could be spent on exercise, meal preparation, or other health-promoting activities. For patients with demanding work schedules or caregiving responsibilities, that time cost is prohibitive.

The decision is not "which program is better" but "which program fits your life well enough that you will actually adhere to it for 12+ months." A theoretically superior program that you abandon after 3 months is worse than a simpler program you complete.

FAQ

What is Genesis Weight Nashville? Genesis Weight Nashville is a medical weight loss clinic offering GLP-1 receptor agonist medications (semaglutide and tirzepatide) combined with nutritional counseling, metabolic monitoring, and body composition analysis. The program requires monthly in-person visits and costs $350-$600 per month depending on medication choice.

Does Genesis Weight use brand-name or compounded GLP-1 medications? Both. Genesis Weight offers brand-name medications (Wegovy, Zepbound, Ozempic, Mounjaro) if insurance covers them, and compounded semaglutide or tirzepatide for self-pay patients. The active ingredient is identical; the difference is manufacturing process and cost.

How much does Genesis Weight cost per month? $350-$400/month for compounded semaglutide programs, $500-$550/month for compounded tirzepatide programs. Brand-name programs cost $25-$50/month if insurance covers the medication, or $1,450-$1,650/month for self-pay brand-name options. All tiers include provider visits, labs, and body composition analysis.

Is Genesis Weight covered by insurance? The provider visit component may be covered if you have insurance that reimburses obesity management services. Medication costs are typically not covered unless you have one of the minority of insurance plans that cover obesity drugs. Most patients pay out-of-pocket for the full program.

How does Genesis Weight compare to telehealth GLP-1 programs? Genesis Weight requires monthly in-person visits and includes metabolic monitoring, body composition tracking, and dietitian access. Telehealth platforms offer medication-only with virtual provider messaging at 40-60% lower cost. Genesis Weight is better for patients with comorbid conditions; telehealth is sufficient for straightforward obesity cases.

Do I need to live in Nashville to use Genesis Weight? You need to be able to attend monthly in-person visits at the Nashville clinic location. Patients who live within a 60-90 minute drive typically find this manageable. Patients outside that radius often find the travel burden unsustainable and switch to telehealth alternatives.

What lab tests does Genesis Weight require? Baseline comprehensive metabolic panel, HbA1c, lipid panel, and TSH. Repeat metabolic panels at 12 and 24 weeks. Additional labs (liver enzymes, kidney function, vitamin levels) ordered if clinically indicated. All labs performed at the clinic or contracted lab facility.

Can I switch from Genesis Weight to a telehealth platform? Yes. If you start with Genesis Weight and later want to switch to telehealth (typically for cost or convenience reasons), you can transfer care. Your medical records and current dose information transfer to the new provider. Most patients switch after completing initial titration to maintenance dose.

What happens if I miss a monthly Genesis Weight appointment? Missed appointments delay medication refills and dose escalations. The clinic typically allows one missed appointment per quarter before requiring re-evaluation. Chronic missed appointments result in discharge from the program, as monthly monitoring is a core component of the care model.

Does Genesis Weight treat patients with type 2 diabetes? Yes. Patients with type 2 diabetes are eligible and often benefit more from the integrated care model, especially if taking insulin or other diabetes medications that require coordination. The clinic adjusts diabetes medications as GLP-1s improve glucose control to prevent hypoglycemia.

What is the average weight loss on Genesis Weight programs? The clinic reports 15-22% total body weight loss at 12 months for patients who complete the full program, consistent with published semaglutide and tirzepatide trial outcomes. Individual results vary based on starting weight, adherence, diet, and exercise habits.

Can I use Genesis Weight if I've tried GLP-1 medications before? Yes. Patients who previously tried semaglutide or tirzepatide through other providers can enroll. The clinic reviews prior dosing history, reasons for discontinuation, and side effect profile to optimize the new treatment plan. Prior GLP-1 use is not a contraindication.

What if I have side effects on Genesis Weight medications? The monthly visit structure allows rapid dose adjustments if side effects occur. Common side effects (nausea, constipation, fatigue) are managed with dose reduction, slower titration, or supportive medications. Severe side effects (pancreatitis, gallbladder disease) result in immediate discontinuation and specialist referral.

Does Genesis Weight offer financing or payment plans? Payment policies vary. Contact the clinic directly to ask about payment plan options. Some patients use healthcare credit cards (CareCredit) or health savings accounts (HSA/FSA) to manage monthly costs.

How long do I need to stay on Genesis Weight programs? Most patients complete 12-18 months of active weight loss, then transition to maintenance dosing. Some patients continue indefinitely; others taper off medication after reaching goal weight. Discontinuation rates are higher in the first 6 months (20-30%) due to side effects or cost concerns.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Khera R et al. Association of Pharmacological Treatments for Obesity with Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. Obesity Reviews. 2023.
4. Lingvay I et al. Comparative Effectiveness of Telehealth vs Clinic-Based GLP-1 Therapy in Patients with Type 2 Diabetes. Diabetes Care. 2024.
5. Davies MJ et al. Gastric Emptying and Glycemic Control with Tirzepatide vs Placebo. Diabetes Care. 2023.
6. American College of Gastroenterology. Guidelines for the Diagnosis and Management of GERD. 2022.
7. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Obesity. Endocrine Practice. 2016.
8. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021.
9. Aronne LJ et al. Continued Treatment with Tirzepatide for Maintenance of Weight Reduction. JAMA. 2024.
10. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
11. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight. JAMA. 2021.
12. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Lancet. 2021.
13. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Advances in Therapy. 2018.
14. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials. Obesity. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Genesis Weight, Wegovy, Ozempic, Zepbound, Mounjaro, LabCorp, Quest, CareCredit, and GoodRx are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.